Please ensure Javascript is enabled for purposes of website accessibility

Why Aurinia Pharmaceuticals Stock Is Flying Today

By George Budwell - Jan 25, 2021 at 4:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA approved the drugmaker's closely watched lupus nephritis therapy.

What happened

Shares of Aurinia Pharmaceuticals (AUPH -1.61%), a mid-cap biotech company, closed trading Monday up by a healthy 26%. The stock raced higher in response to the FDA's approval of the company's oral lupus nephritis drug, Lupkynis (aka voclosporin).

Lupkynis is indicated for patients with active lupus nephritis who are already receiving background immunosuppressive therapy. Lupus nephritis is an advanced form of systemic lupus erythematosus, an autoimmune disorder that can lead to irreversible kidney damage, dialysis, and even death. Lupkynis is the first oral therapy approved for this condition. 

A rocket taking off.

Image source: Getty Images.

So what

Approximately 100,000 adults in the U.S. are currently afflicted by lupus nephritis, per Aurinia's own estimates. A similar number are believed to suffer from the condition in Europe. While that makes it relatively uncommon, Aurinia said that it expects to net roughly $65,000 per patient on annual basis after accounting for rebates, channel discounts, and patients discontinuing therapy early. Wall Street analysts, in turn, think this important new lupus nephritis therapy could generate sales in excess of $1 billion per year early on in the new decade. 

Now what

Is Aurinia's stock still a buy after Monday's sizable move northward? Although it could take a few years for sales of Lupkynis to ramp up, the company does appear to be a strong buyout candidate in the wake of this approval. Aurinia's market cap, after all, is still under $2.5 billion at the time of writing. Even at a price tag of say, $5 billion, it would be a downright bargain for any of the big pharmas that have interests in lupus. In short, this mid-cap biopharma stock may be worth adding to your portfolio soon. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
AUPH
$10.99 (-1.61%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.